ImaBiotech Supports the Institut Pasteur de Lille and Apteeus for the Development of Covid-19 Therapy
ImaBiotech, the worldwide leading provider of innovative imaging services joined the fight against the Covid19 by putting its expertise at the service of the drug candidate TEE001, currently in development by Institut Pasteur de Lille and Apteeus, to demonstrate its capacity at reducing infection by the SARS-CoV2 virus. This partnership aims at providing insight into the whole-body distribution of the drug related material.
The active ingredient of the drug already marketed in few countries has been identified in the Apteeus TEE Library with a profile that met the specifications of a good candidate drug against SARS-CoV2 virus. Faced with the pressures of a global pandemic, ImaBiotech’s objective was to measure…….